CTIS2023-503587-17-00
Recruiting
Phase 1
A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies - MK-4280-003
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 140
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Has measurable disease, defined as \=1 lesion that can be accurately measured in 2 dimensions with diagnostic quality cross sectional anatomic imaging (computed tomography or magnetic resonance imaging). Minimum measurement must be \>15 mm in the longest diameter or \>10 mm in the short axis, Is able to provide a core or excisional tumor biopsy for biomarker analysis from an archival (within 3 months) or newly obtained biopsy at screening, Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
Exclusion Criteria
- •Has known clinically active central nervous system (CNS) involvement, Has a known additional malignancy that is progressing or requires active treatment with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy, Has active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs), Has a history of (non\-infectious) pneumonitis that required steroids or current pneumonitis, Has an active infection requiring intravenous systemic therapy, Has a known history of human immunodeficiency virus (HIV) infection, Has known, active hepatitis B or hepatitis C infection, Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment, Has had an allogeneic hematopoetic stem cell/solid organ transplantation within the last 5 years, Has received prior therapy with an anti\-lymphocyte activation gene\-3 (LAG\-3\) antibody, Has received chimeric antigen receptors (CAR)\-T\-cell therapy for classical Hodgkin lymphoma (cHL) and diffuse large B\-cell lymphoma (DLBCL) Cohorts, Has received prior anticancer therapy or thoracic radiation therapy within 14 days before the first dose of study treatment, Has \=Grade 2 non\-hematological residual toxicities from prior therapy, Has had a prior anticancer monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., \=Grade 1 or at baseline) from AEs due to agents administered \=4 weeks earlier, Has received a live vaccine within 30 days prior to first dose of study treatment. Administration of killed vaccines are allowed, Has received an investigational agent or used an investigational device within 4 weeks prior to intervention administration, Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
MK-4280 and Pembrolizumab in Hematologic MalignanciesHematologic malignanciesMedDRA version: 21.1Level: LLTClassification code 10025315Term: Lymphoma malignantSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-001461-16-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.84
Active, not recruiting
Phase 1
MK-4280 and Pembrolizumab in Hematologic MalignanciesHematologic malignanciesMedDRA version: 21.1Level: LLTClassification code 10025315Term: Lymphoma malignantSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-001461-16-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.84
Completed
Phase 2
Investigator-initiated Phase 2 clinical study of S-005151 in patients with osteoarthritis of the kneeOsteoarthritis of the kneeJPRN-jRCT2021200034Ishibashi Yasuyuki20
Active, not recruiting
Phase 1
A Phase II Pilot Study to Assess Safety and Efficacy of Sodium Valproate in Adults with McArdle DiseaseMcArdle disease (Glycogen storage disease type V, GSDV). The condition is an inherited disorder of skeletal muscle that causes exercise intolerance. The condition can give way to potential rhabdomyolysis which can cause acute renal failure and from middle age muscle wasting and weakness. Affected patients are unable to produce lactate during ischaemic exercise due to a congenital lack of the enzyme muscle glycogen phosphorylase which is essential for glycogen metabolism.MedDRA version: 16.1 Level: LLT Classification code 10026969 Term: McArdle's disease System Organ Class: 100000004850Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2012-002933-12-GBniversity College London,8
Active, not recruiting
Not Applicable
Study of a new drug combination to treat Chronic Lymphocytic Leukemiantreated or Relapsed Chronic Lymphocytic LeukaemiaMedDRA version: 14.1Level: LLTClassification code 10008968Term: Chronic lymphocytic leukaemia stage A(0)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2011-005178-43-ITGLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.80